United States Liquid Biopsy Market Report 2023 and 2024-2032 Featuring Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad, Biocept, Biocartis, Myriad Genetics, Exact Sciences, NeoGenomics, Quest - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been add
BusinesswireApr 23 12:19 ET
Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health. That number jumps to nearly 80% for those diagnosed with anxiety
GlobeNewswireApr 17 08:00 ET
Express News | Myriad Genetics Inc : BofA Global Research Cuts Price Objective to $18 From $22
Moomoo 24/7Apr 17 06:25 ET
Express News | Myriad Genetics Inc : TD Cowen Cuts Target Price to $23 From $26
Moomoo 24/7Apr 17 06:02 ET
Express News | New Myriad Genetics Published Study Demonstrating PPV For 22122.2 Microdeletion Screening Using Prequel Prenatal Screen
Moomoo 24/7Apr 16 09:18 ET
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel Prenatal Screen
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a study1 demonstrating
GlobeNewswireApr 16 09:15 ET
Express News | Myriad Genetics Inc : Guggenheim Raises Target Price to $25 From $23
Moomoo 24/7Apr 16 06:40 ET
Myriad Genetics (MYGN) Announces Favorable Research Results
Yahoo FinanceApr 11 10:00 ET
ACMG Foundation for Genetic and Genomic Medicine Elects Four Highly Accomplished Medical Genetics Professionals to Its Board of Directors
BETHESDA, Md., April 11, 2024 /PRNewswire/ -- The ACMG Foundation for Genetic and Genomic Medicine (ACMGF) announced today that Marilyn C. Jones, MD, FACMG; Harry Ostrer, MD, FACMG; Lisa G. Shaffer,
PR NewswireApr 11 09:30 ET
Form 144 | Myriad Genetics(MYGN.US) Insider Proposes to Sell 1.5 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 10, $Myriad Genetics(MYGN.US)$ Insider Richard Bryan Riggsbee intends to sell 75,000 shares of its common stock on Apr 10, with a total market value of approximately $1.5 m
moomoo NewsApr 10 16:04 ET
Express News | Myriad Genetics Research Shows Reduction In Hospitalizations For Patients With Depression After GeneSight Testing
Moomoo 24/7Apr 9 08:05 ET
Is Myriad Genetics (NASDAQ:MYGN) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
Simply Wall StApr 1 06:44 ET
Novavax (NVAX) Down 3.2% Since Last Earnings Report: Can It Rebound?
Yahoo FinanceMar 29 11:30 ET
Express News | Reported Earlier, Myriad Genetics Granted Foundational Patent For Molecular Residual Disease (MRD) With Early Priority Date
Moomoo 24/7Mar 22 03:14 ET
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) With Early Priority Date
SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued
GlobeNewswireMar 21 21:40 ET
Express News | Myriad Genetics Says US Patent And Trademark Office Has Granted Patent That Covers Use Of Push-Button Blood Collection Devices For PCR-Based Fetal Sex Determination
Moomoo 24/7Mar 20 16:08 ET
Myriad Genetics Announces Patent Granted for SneakPeek Snap Device
SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office has granted a
GlobeNewswireMar 20 16:05 ET
Piper Sandler Sticks to Their Hold Rating for Myriad Genetics (MYGN)
TipRanksMar 6 07:36 ET
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 82% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Myriad Genetics fair value estimate is US$40.03 Myriad Genetics' US$21.97 share price signals that it might be 45% undervalued Our fair val
Simply Wall StMar 5 08:12 ET
Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact
Yahoo FinanceMar 1 09:41 ET
No Data
No Data